Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Interview with Robert Galarza, Director and CEO of TruTrace Technologies (CSE: $TTT.C) (OTC: $TTTSF)
Delta, Kelowna, BC –October 1, 2019 (Investorideas.com Newswire)
(Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/10011Interview-RobertGalarza-CSETTT.asp
In today’s podcast I interview Robert Galarza, Director and CEO of TruTrace Technologies Inc. (CSE: TTT) (OTC: TTTSF), where we discussed the company’s pilot program with Shoppers Drug mart and future of the cannabis industry.
TruTrae’s “Pilot Program” recently completed Phase 1 and is moving into Phase 2, where the company is beginning to gain real traction with industry names such as it’s recent partnership with Deloitte as well as having one of the larger LP’s Aphria join the pilot progam as well.
Robert commented on the completion of Phase 1 and moving into Phase 2, saying, “In our years in the industry, we really started to understand that the most important data point on the product, in terms of medical efficacy, or trust, or product integrity was the identification of the product. You can’t really track/trace anything else unless you really know what it is. Genetic and chemistry testing, associated with these products really held the key. There’s a lot of great chemistry out there, but genetics is the one thing that can’t change on a product line in a clone based propagation, if you have a consistent and visible supply chain. In this world of buying and selling inventory from different LP’s, I think everyone is wanting a really strong level set on exactly what this product is.”
Robert continued, “It’s a really amazing thing when you get introduced to the largest pharmacy in Canada (Shoppers Drugmart). They’re the Walgreens and CVS combined in Canada. What blew us away was their knowledge of cannabis. They had been in this industry for six years quietly behind the scenes, and they understood all of it. They understood the black market, the grey market, the MMAR, the MNPR, the designated cultivators, the growers, everything associated with this industry they understood at a deep level, and they were running into a consistent challenge, which was: as a medical practitioner there’s no romance about cannabis. Everything is about facts and medicine and research and information. They were running into the same problem that we saw which was there’s no integrity and standardization behind these products. Our platform at its core really resonated with them. Phase 1 was initial stage implementation of the core platform into the Shoppers ecosystem and into an initial LP WeedMD, who was out first client, and getting that through line to show that it could all work. Phase 2 has been about onboarding the other suppliers and having Deloitte to come in and help us manage the scope of the project. Even with seven large licensed producers, it’s a lot of moving parts. What’s been amazing is once we’ve built the system where we’ve validated that product, and we’ve got the security and visibility at the core of our information, it’s amazing who wants access to that information. That’s where the physician networks and hospital networks have popped up.”
When asked about the different approach TruTrace has taken in the U.S. market versus the Canadian market Robert commented, “In the U.S. we’ve taken a little bit of a different approach. Because of the federal landscape here, we’re kind of planting the seed as we don’t know exactly what the future is going to hold for the United States. Those of us that have lived here and been involved in the marketplace are of the belief that we will see medical legalization occur in the next couple of years. What that allows, is it allows patients to access safe medicine in all jurisdictions across the country and it allows the FDA to come in and implement the kind of standards and practices around testing so people are getting safe product. Safe product is the key. You can’t just open the thing up to open market capitalism.”
Robert continued to talk about the potential of TruTrace moving forward and the possibilities for collaborations in the future as well as trends being noticed in the cannabis market.
If you enjoyed this podcast we recommend listening to our interview with Andrew Muroff from StrainPrint Technologies here.
https://www.investorideas.com/news/2019/cannabis-potcasts/09201Interview-StrainprintTechnologies.asp
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment